Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGMO vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Captures Overall Composite Edge (41.9 SELL vs 52.0 HOLD), While SGMO Leads 4–1 on Growth & Valuation Pillars

CLYM Overall Winner 6-Pillar Tally: SGMO 4 – 1 CLYM (1 Tie) Matrix Metrics: SGMO 4 – 5 CLYM

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (41.9/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while SGMO wins 4–1 across the 6-pillar growth and valuation breakdown. SGMO trades at $0.18 (0.4x Forward P/E, -175.5% operating margin) versus CLYM at $9.99 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY).
  • Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGMO vs CLYM
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.99
-3.52% 1D
Market Cap $638.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.51β · 114% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $10.28 · SMA50: $11.47

6-Pillar Scorecard Institutional Category Breakdown (SGMO 4 – 1 CLYM)

Columns: Metric · SGMO · CLYM
1. Valuation Multiples SGMO
Forward P/E 0.4x N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 1.2x N/M
2. Growth & Scale SGMO
Revenue Growth (YoY) +88.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $40M N/A
Market Cap $55.9M $638.5M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin -175.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -2891.8% -29.3%
4. Balance Sheet & Cash Flow SGMO
Cash Generation (TTM) -$90M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $8.3M Net Cash $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 144.2% (71st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGMO (4) vs CLYM (5)
Institutional Metric SGMO CLYM Criterion Row Edge
Market Capitalization
Scale
$55.9M $638.5M Larger Scale CLYM
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple SGMO
Forward P/E Ratio
Valuation
0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY)
Growth
+88.4% +0.0% Higher Growth SGMO
Operating Margin (TTM)
Profitability
-175.5% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-2891.8% -29.3% Higher ROE CLYM
52-Week Range Position
Momentum
9% ($0–$1) 50% ($2–$18) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.49β · 206% Vol 1.51β · 114% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 41.9 / 100 (SELL) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
$40M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$90M ($8.3M Net Cash) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLYM +88.53 pp
SGMO: -40.82% · CLYM: +47.71%
3M Horizon CLYM +173.59 pp
SGMO: -68.73% · CLYM: +104.86%
6M Horizon CLYM +478.64 pp
SGMO: -60.46% · CLYM: +418.18%
1Y Horizon CLYM +478.64 pp
SGMO: -60.46% · CLYM: +418.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGMO vs CLYM. Trailing 12-month operating profitability (SGMO -175.5% vs CLYM 0.0%) and valuation multiples (SGMO 0.4x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SGMO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross MarginN/A
Op. Margin-175.5%
ROE / Fwd P/E-2891.8% · 0.4x
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $638.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGMO vs CLYM Key Questions & Quantitative Answers

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (41.9/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while SGMO wins 4–1 across the 6-pillar growth and valuation breakdown. SGMO trades at $0.18 (0.4x Forward P/E, -175.5% operating margin) versus CLYM at $9.99 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY). Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: SGMO posts +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SGMO generates $40M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, SGMO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

SGMO screens cheaper on headline valuation multiples. SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMO (-2891.8% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.51β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.